Headshot of Gaelle Chapuis.

Gaëlle Chapuis

Director of operations and outreach
International Brain Laboratory

Gaëlle Chapuis is a director and technical manager responsible for overseeing the activities of the International Brain Laboratory, a global consortium of 21 institutions and more than 75 people, aimed at understanding how brain activity patterns lead to decision-making. Chapuis is based in Geneva and supervises a team of engineers deployed in five countries. Her group provides support to scientists, creating professionalized workflows that are adopted at a large scale. She also supervises the outreach efforts of the consortium. So far, more than 40 research projects in and outside of the International Brain Laboratory have benefited from these technologies and organizational developments.

After earning a B.Sc. in microengineering at the Swiss Federal Technology Institute of Lausanne (EPFL), Chapuis pursued an M.Sc. in biomedical engineering with a specialization in neurotechnology at Imperial College London. She then undertook several research projects in the field of sensory neuroscience at EPFL; the University of California, San Francisco; and University College London before completing a Ph.D. at Imperial College London in the laboratory of Paul Chadderton.

Explore more from The Transmitter

Hand holding a vial of microplastics.

Measuring plastic in the brain: Improving, but incomplete

Meanwhile, researchers are publishing papers without “sufficient quality control,” says analytical chemist Dušan Materić.

By Amber Dance
18 September 2026 | 9 min read
Calendar with deadline.

Incredible shrinking grant deadlines at the BRAIN Initiative

“A month is crazy,” says one former recipient, referring to a new funding opportunity’s timeline.

By Brendan Borrell
17 September 2026 | 4 min read

Sylvia Fogel, reshaping U.S. autism research strategy

In a wide-ranging and provocative interview, the chair of the federal Interagency Autism Coordinating Committee shares her views on vaccines, regression, neuroimmune conditions and more.

By Brady Huggett
17 September 2026 | 1 min read